stockportfolio.pro
Bioventus Inc. (BVS)
Healthcare · Medical Devices · NasdaqGS
Bioventus Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $340.14M | $321.16M | $430.90M | $512.12M | $512.35M | $573.28M | $568.09M |
| Gross profit | $249.21M | $233.52M | $302.71M | $331.08M | $328.19M | $388.23M | $388.16M |
| Net income | $6.85M | $16.41M | $19.38M | $-158.70M | $-156.23M | $-36.13M | $22.73M |
| Net margin | 2.0% | 5.1% | 4.5% | -31.0% | -30.5% | -6.3% | 4.0% |
Source: Bioventus Inc. SEC filings (10-K).
What growth is priced into BVS stock?
At today's market cap of $590.09M, Bioventus Inc. is priced for free-cash-flow growth of about -4.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $72.11M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 5.5%/yr over the last five fiscal years and revenue 12.1%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 7 years of Bioventus Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BVS in your portfolio →
Bioventus Inc. financial history by metric
About Bioventus Inc.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Bioventus Inc. — frequently asked questions
What is Bioventus Inc.'s revenue?
Bioventus Inc. (BVS) reported revenue of $568.09M for fiscal year 2025, down 0.9% from the prior year, according to its SEC filings.
Is Bioventus Inc. profitable?
Yes. BVS earned net income of $22.73M in fiscal 2025, a net margin of 4.0%.
What is BVS's P/E ratio?
Bioventus Inc. trades at a price-to-earnings ratio of about 21.2 based on the latest data in our nightly-refreshed cache.
How fast is Bioventus Inc. growing?
BVS's revenue grew at roughly 12.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Bioventus Inc. have?
As of fiscal year 2025, BVS carried roughly $293.95M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Bioventus Inc.'s gross margin?
BVS's gross margin was 68.3% in fiscal 2025 — gross profit of $388.16M on revenue of $568.09M.
What is Bioventus Inc.'s market cap?
Bioventus Inc. (BVS) has a market capitalization of about $590.09M, based on the latest data in our nightly-refreshed cache.
When does Bioventus Inc.'s fiscal year end?
BVS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into BVS stock?
At today's market cap of $590.09M, Bioventus Inc. is priced for free-cash-flow growth of about -4.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $72.11M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 5.5%/yr over the last five fiscal years and revenue 12.1%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Bioventus Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.